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Background: The polyglutamine (polyQ) family of disorders comprises 9 genetic diseases, including several types
of ataxia and Huntington disease. Approximately two decades of investigation and the creation of more than 130
mouse models of polyQ disorders have revealed many similarities between these diseases. The disorders share
common mutation types, neurological characteristics and certain aspects of pathogenesis, including morphological
and physiological neuronal alterations. All of the diseases still remain incurable.
Description: The large volume of information collected as a result of the investigation of polyQ models currently
represents a great potential for searching, comparing and translating pathogenesis and therapeutic information
between diseases. Therefore, we generated a public database comprising the polyQ mouse models, phenotypes
and therapeutic interventions tested in vivo. The database is available at http://conyza.man.poznan.pl/.
Conclusion: The use of the database in the field of polyQ diseases may accelerate research on these and other
neurodegenerative diseases and provide new perspectives for future investigation.
Keywords: Polyglutamine diseases, Mouse models, Database, Neurodegenerative disease, Therapy, Huntington
disease, Spinocerebellar ataxia, DRPLA, SBMABackground
Polyglutamine (polyQ) diseases are evoked by a special
type of mutation whereby the expansion of CAG trinu-
cleotide repeats in coding exons of causative genes oc-
curs. Nine diseases with this type of mutation have been
identified, including Huntington disease (HD) [1];
spinocerebellar ataxia (SCA) type 1 [2], type 2 [3],
Machado-Joseph disease (MJD/SCA3) [4], type 6 [5],
type 7 [6], and type 17 [7, 8]; dentatorubral pallidoluy-
sian atrophy (DRPLA) [9, 10]; and spinal and bulbar
muscular atrophy (SBMA) [11, 12]. All of these condi-
tions are neurological disorders that share several com-
monalities, including similar mutation genetics and
numerous aspects of pathogenesis. All of these disorders
are rare. However, these conditions are highly significant
for understanding pathogenic mechanisms in neurode-
generation because the defined etiology of polyQ* Correspondence: mfigiel@ibch.poznan.pl
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(http://creativecommons.org/publicdomain/zediseases induces a spectrum of neurological symptoms
in patients. Enormous interest in polyQ diseases has led
to the generation of more than 130 mouse models, and
investigation of these models has helped define polyQ
pathogenesis. Therefore, the research continues with
new models being generated and published [13, 14].
The neurological features of polyQ disorders in pa-
tients include, motor abnormalities, such as gait ataxia,
sensory defects, ocular, speech, cognitive and other
symptoms. All symptoms become evident in the third or
fourth decade of life and the severity is mainly
dependent on length of the CAG expansion and other
genetic modifiers. The mechanisms of pathogenesis in
polyQ diseases have been discussed also recently
[15–18]. In brief, the relevant pathogenesis is based on
the toxic function of the mutant polyQ proteins. Long
polyglutamine domain in causative proteins misfolds and
aggregates into cytoplasmic and nuclear insoluble
inclusions. Both inclusions and soluble polyglutamine
domains interact with various cellular components
exerting a spectrum of cellular dysfunction includingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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clearance machinery impairment, increased susceptibility
to excitotoxicity, inflammation and oxidative damage,
and apoptosis induction [19, 20]. The elucidation of
these mechanism was possible because of generation
and investigation of the animal models, creating enor-
mous data volume about pathogenesis and therapy
which was the main requirement for creation of dedi-
cated database.
Mice as model organisms are small, easy to breed and
available in different strains, thus constituting a cost-
effective genetic platform. Various biotechnology tools
are available to modify the mouse genome, including
embryonic stem cells, vectors and recent gene editing
tools, such as zinc-finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs) and clustered
regulatory interspaced short palindromic repeats (CRISPRs)
[21, 22]. Finally, there are also various online resources pro-
viding information about the biology of the mouse, includ-
ing the complete sequence of the mouse genome, gene
expression atlases in various tissues, mouse anatomy atlases
and databases of mouse behavior. The best known re-
sources include the Mouse Genome Informatics database
(http://www.informatics.jax.org/) [23], Allen Mouse Brain
Atlas (http://www.brain-map.org) [24], EBI Gene Ex-
pression Atlas (http://www.ebi.ac.uk/gxa/home) [25],
Ensembl (www.ensembl.org) [26], NCBI online ser-
vices (http://www.ncbi.nlm.nih.gov) [27] and many
others.
We previously generated electronic resources in the form
of Excel-based databases/tables containing more than 4000
records describing the pathogenesis and therapeutic ap-
proaches in polyQ mouse models [19, 20]. We now present
an online public database that contains updated polyQ
mouse model data in a format that is easy to search, com-
pare and integrate the information across polyQ models.
Results
Database content
The most recent version of the database comprises data on
the mouse models of 9 polyQ diseases. It contains basic in-
formation about the mouse models, such as their genetic
design, and detailed descriptions of the disease phenotypes.
Moreover, the database contains information regarding
therapeutic approaches evaluated in polyQ mice, including
information about drugs and the phenotypes that were
evaluated as therapeutic outcomes. Figure 1 presents the
current structure of the database (see Materials and
methods). Table 1 presents the overall number of records
for selected tables and short description of the records.
Online interface and query of the database
The online interface to the database is organized as a
web page with a “Search” tab and three thematic tabsentitled “Models”, “Phenotypes” and “Therapies” (Fig. 2a).
The three thematic tabs in the online interface are
designed to present and group the search results with
respect to models, phenotypes and therapies.
Using the “Search” tab, the user may perform a clas-
sic text search, and the results are displayed in the
remaining three thematic tabs “Models”, “Phenotypes”
and “Therapies”. Instead of performing the text search,
the user may also opt to perform an “intuitive” search
using lists and pictograms available in the “Models”,
“Phenotypes” and “Therapies” tabs (Fig. 2b,c). The in-
tuitive search is performed by selecting the disease
and most common mouse models from the list in tab
“Models”, selecting the phenotype location on the brain
diagram (Lein et al. [24]) and pictograms of other central
nervous system (CNS) and non-CNS organs and tissues in
tab “Phenotypes” (Fig. 2b) and selecting from more than
20 therapeutic strategies using 6 icons, which schematic-
ally group the strategies (Fig. 2c).
Keywords to perform a classical text search of the database
To search the database, several types of inputs can be
used, including the diseases (e.g., “HD”, “SCA3”), common
name of model (e.g., “R6/2”, “Ki91”), detailed phenotype
(e.g., “inclusions”, “incoordination”), location (e.g., “cor-
tex”, “cerebellum” or “liver”), detailed location (e.g., “Pur-
kinje”), drug (e.g., “minocycline”) and therapeutic strategy
(e.g., “apoptosis”, “cell therapy”). Keywords can be con-
structed using Boolean operands “AND”, “OR” and “NOT”
which can be used several times in one query or used in
complex queries containing both “AND”, “OR” and NOT.
Original publications can be accessed by searching their
PMID or the first author of the publication.
Search process ultimately yields the search results in
thematic tabs that offer methods to refine the search re-
sults through selections from drop-down lists. Selecting
a record in any of the thematic tabs results in the display
of a detailed mouse model page, which contains a model
name as a header and is focused on a particular model
and either phenotypes or therapies. If both therapies and
phenotypes are available for the given model, the de-
tailed mouse model page allows switching between the
phenotypic and therapeutic views.
Examining the search results in the “Models”,
“Phenotypes” and “Therapies” tabs
The “Models” tab in the online interface mostly collects
data from “Model” and “Model Phenotype” tables present
in the structure of the database. After performing the text
or intuitive search, the “Models” tab will appear first and
present the range of mouse models (Fig. 3a). From within
the “Models” tab, the user is able to select a model, which
will present a detailed mouse model page (Fig. 3b) with
basic information about the particular mouse model, such
Fig. 1 The diagram illustrates the structure of tables in the database. The main orange tables are “Model”, “ModelPhenotype” and “Therapy”. The
connections with circles indicate the source of data supply. The gray and black colors in tables indicate optional and mandatory values respectively
and reflect the way in which the potential records in the back end of the database are generated. Potential record cannot be generated unless all
mandatory fields (black) are not empty. In turn record can be generated also without “gray” (optional) fields
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promoter, transgene and the reference of the original de-
scription of the model. The page with model details also
contains information about genetic background, number
of polyQ, an external link to the JAX Mice Database
webpage and, most importantly, the phenotypes orTable 1 Database content





Models 135 Mouse models of polyQ d
Drugs 294 Small molecule drugs or e
molecules) assessed in pr
ModelPhenotypes 2579 The number represents th
Therapy 2380 The number represents th
for improvement or deter
Publications 669 Total number of publicatitherapeutic approaches in the model. For instance, in
the R6/2 detailed mouse model page, the user can find
that this is a transgenic HD model that contains the
human HD promoter and expresses the N-terminal
fragment of human huntingtin (HTT) protein with a
120 polyQ stretch.iseases
xperimental paradigms (silencing, overexpression or co-expression of
eclinical therapeutic trials using polyQ models
e individual phenotypic records of the 135 mouse models
e individual therapeutic records, i.e., phenotypes assessed therapeutically
ioration of the response to drugs or therapeutic paradigms
ons analyzed to evaluate phenotypes and therapeutic approaches
Fig. 2 (See legend on next page.)
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Fig. 2 The online interface to the database and search mechanisms. a The interface includes a “Search” tab and three thematic tabs namely
“Models”, “Phenotypes” and “Therapies” to display and group the search results with respect to models, phenotypes and therapies. The database
contains an intuitive search interface to easily obtain search results. The intuitive search offers simple clicking on pictograms to find (b) CNS and
non-CNS localization of the phenotypes and (c) therapeutic strategy
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Phenotype” table found in the structure of the database.
The records displayed in the “Phenotypes” tab provide
an overview of the manifestation of the disease in a
mouse model. The phenotypes in the database are
subcategorized into four main types: “cognitive”,
“motor”, “neuropathology” and “other”. Phenotypes in
these groups are further subdivided into “phenotype”
and “detailed phenotype”, which provide additional
levels of phenotype complexity and enabling a method-
ical incorporation into the database. The above structure
of the phenotype description is reflected in the “Pheno-
types” tab. The records presented in the “Phenotypes”
tab show phenotype manifestation in a particular model,
its details, disease, model name and the reference. TheFig. 3 The “Models”, “Phenotypes” and “Therapies” thematic tabs. a Search
displayed first (default setting) revealing a list of mouse models. The search
page in the phenotype mode is displayed after selecting a model in the “M
model page contains a list of phenotypes that can be expanded to visualiz
approach in “Therapies” tab will open a detailed mouse model page in the
expanded to visualize the box with detailed informationsearch can further be refined using parameters, such as
location of the phenotype in tissues selectable from
dropdown lists. Selecting a model in “Phenotypes” tab
opens a detailed mouse model page in the “phenotype
mode” (Fig. 3b). The detailed mouse model page in this
mode provides a list of phenotypes, which can be ex-
panded or collapsed again to visualize or hide the
detailed description box for each phenotype. The de-
tailed box for each phenotype (Fig. 3c) contains a graph-
ical representation of the age of mice when the
phenotype is manifested, the information about the de-
creased or increased phenotype in mutant mice com-
pared with wild type (WT) mice, number of repeats in
the transgene (Q number), genetic background of mice
and the Pubmed link.results are available in all thematic tabs and the tab “Models” is
can be further refined using dropdown lists. b Detailed mouse model
odels” tab or a phenotype in “Phenotypes” tab. c The detailed mouse
e the detailed box for each phenotype. d Selecting a therapeutic
“therapeutic mode”. Each therapeutic record from the list can be
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proaches using data from “Therapy” table found in the
structure of the database. The therapeutic approaches
listed in the “Therapies” tab contain the therapeutic
strategy, drug that was applied to the mouse model, dis-
ease, model name and the reference. Similar to other
thematic tabs, selecting a therapeutic approach will open
a detailed mouse model page in the “therapeutic mode”.
The detailed mouse model page in this mode provides a
list of therapeutic records, each containing a drug, the
respective mouse phenotype and detailed phenotype that
was affected by the drug and the color-coded therapeutic
outcome. Each therapeutic record from the list can be
expanded or collapsed to visualize or hide the detailed
box. The detailed box for each therapeutic record con-
tains details, such as drug feature or aim, delivery route,
therapeutic strategy, method of quantification of the
therapeutic effect, effect on this phenotype, and de-
scription of the effect by listing whether “mutant vs.
WT” and “treat vs. mock” was “decreased” or “in-
creased” (Fig. 3d).
Interaction with users
The database also contains a dedicated “submit data”
page where research publication from Pubmed contain-
ing mouse models can be submitted to the database for
further verification by database administrators. The
dataset of the database is also available for research users
upon request by e-mail to mfigiel@ibch.poznan.pl. In
addition, the database is open for models of other neuro-
logical diseases, such as Alzheimer and Parkinson, and
also for other model species.
Discussion
Researchers in the polyQ field have generated and pub-
lished 135 polyQ mouse models for 9 diseases over a
period of approximately 20 years. The research over the
years has been a great success and reflects the intensity
of gaining a better understanding of the pathogenesis of
polyQ diseases from an average of 7 models per year. As
a result, numerous therapeutic strategies are now being
tested for these diseases. The aforementioned volume of
data available regarding the pathogenesis and preclinical
therapies of polyQ diseases was the motivation behind
the generation of this database. Therefore, we created
one comprehensive digital repository of polyQ mouse
models. This repository enables both broad and selective
exploration of data on existing models, phenotypes and
experimental therapeutic approaches for polyQ neuro-
logical diseases. Another motivation in generating a ded-
icated database was the fact that all polyQ diseases share
important similarities. The most basic shared features
are their common mutation type, neurological character-
istics and the fact that several polyQ diseases areindistinguishable based only on the clinical features of
patients and the phenotypes in animal models. More-
over, the diseases share commonalities in gene expres-
sion profiles; degeneration of common cell types in the
brain, such as Purkinje cells; or even commonalities with
other neurological diseases, such as accumulation of
amyloid beta and tau protein [28, 29]. Therefore, the
study of a polyQ disease may shed light on the patho-
genic mechanism of other neurologic disorders, and this
database may serve as an appropriate tool to achieve this
aim.
Mouse model database has previously been repre-
sented by Mouse Genome Informatics (MGI) databases
[23] and The International Mouse Phenotyping Consor-
tium [30, 31]. In addition, a database of models available
from a repository is maintained by The Jackson Labora-
tory (http://www.jax.org/). The MGI database is a valu-
able resource providing a digital repository of mouse
models of all known human diseases, including the polyQ
disorders. The function of the MGI database is to
provide a global overview of diseases and models.
Therefore, our database is a response to the need of
a smaller, more detailed and focused, manually cu-
rated database. For instance, the increased “reso-
lution” of our database is reflected in the detailed
description, such as the tissue location of the pheno-
type, direct access to the reference, age of the ani-
mal and how the phenotype was altered compared
with the WT animal. Another innovative aspect of
the database that is not found elsewhere is the avail-
ability of the therapeutic approaches and strategies
to combat polyQ disorders. Additionally, the thera-
peutic section presents a higher level of details
indicating whether the therapy was beneficial, not
beneficial or deleterious.
Conclusions
Taken together, the polyQ model database provides the
latest and most detailed phenotypic and therapeutic in-
formation about polyQ mice. Therefore, we anticipate
that this database will help in elucidating the disease
mechanisms and planning new effective treatments.
Materials and methods
Software tools
Previously published Excel data tables were used as the
initial source of data for the database [19, 20]. The data-
base was generated using the open source PostgreSQL
9.1.13 database engine (The PostgreSQL Global Devel-
opment Group, http://www.postgresql.org). Direct access
to the database is possible at the level of Apache2 server
(The Apache Software Foundation, Forest Hill, MD,
USA; http://www.apache.org/). The internet application
was created using Python 2.7.3 language with the use of
Szlachcic et al. Molecular Brain  (2015) 8:69 Page 7 of 8appropriate libraries (https://pypi.python.org/pypi) (The
Python Software Foundation; https://www.python.org/).
Searching of the database contents is provided by imple-
mentation of Elastic browser version 0.90.10 (Elasticsearch
BV, Mountain View, CA, USA; https://www.elastic.co).
Structure of the database
The structure of the database is based on 15 tables
(Fig. 1). The core consists of the 3 most important tables
named “Model”, “Model Phenotype” and “Therapy”. The
“Model” table describes the mouse model and collects data
from tables “Disease”, “Species”, “Promoter”, “Transgenic
Construct”, “Model Type” and “Publication”. The “Model”
table delivers the collected data to the “Model Phenotype”
and “Therapy” tables. Both tables are supplied with data
about the phenotypes from 3 tables named “General
Phenotypes”, “Phenotypes” and “Detailed Phenotypes”.
Currently, the data in our database are limited to
polyQ diseases; however, the structure of the database
has been built to include other model species, such as
rat, ape, sheep, and cat (“Species” table), and other dis-
eases, such as Alzheimer or Parkinson Disease (“Disease”
table), without further adjustments.
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